BPMC vs. FTSV, TPTX, CLDX, DCPH, SDGR, ALNY, TEVA, GMAB, RPRX, and BGNE
Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Forty Seven (FTSV), Turning Point Therapeutics (TPTX), Celldex Therapeutics (CLDX), Deciphera Pharmaceuticals (DCPH), Schrödinger (SDGR), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), and BeiGene (BGNE).
Blueprint Medicines (NASDAQ:BPMC) and Forty Seven (NASDAQ:FTSV) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, community ranking, institutional ownership, earnings, valuation and profitability.
In the previous week, Blueprint Medicines had 7 more articles in the media than Forty Seven. MarketBeat recorded 8 mentions for Blueprint Medicines and 1 mentions for Forty Seven. Blueprint Medicines' average media sentiment score of 1.04 beat Forty Seven's score of 0.00 indicating that Blueprint Medicines is being referred to more favorably in the media.
Forty Seven has a net margin of 0.00% compared to Blueprint Medicines' net margin of -102.15%. Forty Seven's return on equity of -50.38% beat Blueprint Medicines' return on equity.
Forty Seven has lower revenue, but higher earnings than Blueprint Medicines. Forty Seven is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.
Blueprint Medicines has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Forty Seven has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500.
Blueprint Medicines presently has a consensus target price of $103.94, suggesting a potential upside of 1.56%. Given Blueprint Medicines' higher possible upside, equities analysts plainly believe Blueprint Medicines is more favorable than Forty Seven.
Blueprint Medicines received 378 more outperform votes than Forty Seven when rated by MarketBeat users. However, 68.12% of users gave Forty Seven an outperform vote while only 67.84% of users gave Blueprint Medicines an outperform vote.
71.8% of Forty Seven shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by insiders. Comparatively, 37.4% of Forty Seven shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Blueprint Medicines beats Forty Seven on 10 of the 18 factors compared between the two stocks.
Get Blueprint Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Blueprint Medicines Competitors List
Related Companies and Tools
